Table 5.
Mean (± SD) annual costs (CNY) per patient overall and stratified by MS severity.
| Costs, mean (SD) | Overall (N = 370) | Mild disease (EDSS 0–2.5) (N = 133) | Moderate disease (EDSS 3–5.5) (N = 129) | Severe disease (EDSS 6 +) (N = 108) | p–value |
|---|---|---|---|---|---|
| Direct medical cost | |||||
| Hospitalization* | 2411 (4441) | 1353 (3669) | 2608 (4623) | 3477 (4823) | < 0.001 |
| Consultation* | 330 (228) | 314 (290) | 307 (189) | 378 (174) | < 0.001 |
| Test | 3352 (1727) | 2604 (1397) | 3446 (1703) | 4163 (1743) | < 0.001 |
| Symptomatic treatment | 6129 (9166) | 4106 (7805) | 6645 (9150) | 8003 (10,271) | < 0.001 |
| Concomitant condition | 34,073 (39,072) | 12,979 (25,526) | 37,052 (38,647) | 56,492 (44,038) | < 0.001 |
| DMT | 23,824 (50,809) | 23,923 (40,890) | 30,557 (53,933) | 15,660 (56,907) | 0.010 |
| Total direct medical costs | 70,119 (63,608) | 45,278 (51,141) | 80,615 (62,418) | 88,172 (69,548) | < 0.001 |
| Direct non-medical cost | |||||
| Adaptations (e.g. aids, home modifications) | 3481 (10,738) | 4089 (15,224) | 3345 (7248) | 2896 (6930) | 0.004 |
| Non-medical costs (e.g. transportation) | 946 (1401) | 1011 (1724) | 928 (1452) | 1011 (1724) | 0.143 |
| Professional care | 9293 (41,624) | 1454 (9245) | 6353 (27,881) | 22,456 (68,395) | 0.014 |
| Total direct non-medical cost | 13,720 (42,899) | 6554 (18,154) | 10,626 (29,215) | 26,241 (68,449) | 0.001 |
| Indirect cost** | |||||
| Annual patient productivity loss | 17,436 (28,604) | 8089 (18,628) | 20,838 (30,141) | 24,882 (33,591) | 0.033 |
| Annual non-professional caregiver productivity loss | 79,695 (87,277) | 25,870 (54,131) | 78,744 (71,256) | 147,116 (91,597) | < 0.001 |
| Total indirect costs | 97,131 (101,688) | 33,959 (59,169) | 99,582 (84,439) | 171,998 (110,393) | < 0.001 |
| Total cost | 215,748 (183,258) | 98,479 (100,841) | 226,001 (142,877) | 347,915 (209,759) | < 0.001 |
*Hospitalization and consultation costs were calculated using unit cost in hospitalization and consultation excluded test, medication, and symptomatic treatment. **Indirect costs were adjusted using GDP CNY 2021.